Telomir Pharmaceuticals Inc
For the period ended Dec 31, 2023. Filed Mar 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 29, 2024
TELO$0.57-17.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits, Financial Statement Schedules
The information called for by this Item is incorporated herein by reference to the Exhibit Index in this Form 10-K.
INDEX TO EXHIBITS
| Exhibit No. | Exhibit Description |
|---|---|
| 1.1^ | Form of Underwriting Agreement |
| 3.1^ | Second Amended and Restated Articles of Incorporation of Telomir Pharmaceuticals, Inc. |
| 3.2^ | Amended and Restated Bylaws of Telomir Pharmaceuticals, Inc. |
| 4.1^ | Form of Representative’s Warrant |
| 4.2^ | Common Stock Purchase Warrant, dated June 15, 2023, between Telomir Pharmaceuticals, Inc. and Bay Shore Trust |
| 4.3^ | Form of Common Stock Purchase Warrant, by and between the Company and certain investors from January 2023 through March 2023 |
| 4.4** | Description of Securities |
| 10.1+^ | 2023 Omnibus Incentive Plan |
| 10.2+^ | Form of Stock Option Award under 2023 Omnibus Incentive Plan |
| 10.3^ | Form of Indemnification Agreement |
| 10.4^ | Amended and Restated License Agreement, dated August 11, 2023, by and between Telomir Pharmaceuticals, Inc. and MIRALOGX LLC |
| 10.5^ | Amendment No. 1 to Amended and Restated License Agreement, dated November 10, 2023, by and between Telomir Pharmaceuticals, Inc. and MIRALOGX LLC |
| 10.6+^ | Amended and Restated Employment Agreement, dated December 11, 2023, between Telomir Pharmaceuticals, Inc. and Nathen Fuentes, CPA. |
| 10.7+^ | Employment Agreement, effective as of the date of the closing of the initial public offering, between Telomir Pharmaceuticals, Inc. and Dr. Christopher Chapman, Jr., MD |
| 10.8^ | Promissory Note and Loan Agreement, dated June 15, 2023, by and between Telomir Pharmaceuticals, Inc. and Bay Shore Trust |
| 10.9^ | Agreement for Shared Lease Costs, dated April 1, 2023, between Telomir Pharmaceuticals, Inc., MIRALOGX LLC, and MIRA Pharmaceuticals, Inc. |
| 10.10^ | Debt Conversion Agreement, dated November 30, 2023, between Telomir Pharmaceuticals, Inc., and MIRALOGX LLC |
| 10.11^ | Debt Conversion Agreement, dated November 30, 2023, between Telomir Pharmaceuticals, Inc., and the Bay Shore Trust. |
| 14.1^ | Code of Business Conduct and Ethics |
| 21.1^ | List of Subsidiaries of Registrant |
| 31.1** | Certification of Principal Executive Officer, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002* |
| 31.2** | Certification of Principal Financial Officer, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002* |
| 32.1** | Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
| 32.2** | Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
| 97.1** | Policy Relating to Recovery of Erroneously Awarded Compensation |
| 99.1^ | Audit Committee Charter |
| 99.2^ | Nominating and Corporate Governance Committee Charter |
| 99.3^ | Compensation Committee Charter |
| 99.4^ | Corporate Governance Guidelines |
| 99.5^ | Insider Trading Policy |
| 99.6^ | Related Person Transaction Policy and Procedures |
| * | To be filed by amendment. |
|---|---|
| ** | Furnished herewith |
| ^ | Previously filed. |
| + | Denotes management contract or compensatory plan or arrangement. |
TELOMIR PHARMACEUTICALS, INC.
INDEX TO FINANCIAL STATEMENTS
| Report of Independent Registered Public Accounting Firm (PCAOB ID 00677) | F-1 |
|---|---|
| Balance Sheets as of December 31, 2023 and 2022 | F-2 |
| Statements of Operations for the years ended December 31, 2023 and 2022 | F-3 |
| Statement of Stockholders’ Equity (Deficit) for the years ended December 31, 2023 and 2022 | F-4 |
| Statements of Cash Flows for the years ended December 31, 2023 and 2022 | F-5 |
| Notes to Financial Statements | F-6 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.